Mankind Pharma Ltd (MANKIND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mankind Pharma Ltd (MANKIND) has a cash flow conversion efficiency ratio of 0.022x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs1.93 Billion ≈ $20.87 Million USD) by net assets (Rs86.34 Billion ≈ $933.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mankind Pharma Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Mankind Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Mankind Pharma Ltd (MANKIND) financial obligations for a breakdown of total debt and financial obligations.
Mankind Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mankind Pharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brookfield Renewable Partners L.P
TO:BEP-UN
|
0.010x |
|
Pro Medicus Ltd
AU:PME
|
0.178x |
|
Embraer S.A
F:EMY
|
0.225x |
|
Skyverse Technology Co. Ltd. A
SHG:688361
|
N/A |
|
Komercni Banka A.S.
PR:KOMB
|
0.004x |
|
Wintrust Financial Corporation
NASDAQ:WTFC
|
0.029x |
|
Aegon NV
AS:AGN
|
0.132x |
|
NTPC Green Energy Limited
NSE:NTPCGREEN
|
0.023x |
Annual Cash Flow Conversion Efficiency for Mankind Pharma Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Mankind Pharma Ltd from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see MANKIND stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs145.68 Billion ≈ $1.58 Billion |
Rs24.13 Billion ≈ $261.00 Million |
0.166x | -26.30% |
| 2024-03-31 | Rs95.76 Billion ≈ $1.04 Billion |
Rs21.52 Billion ≈ $232.78 Million |
0.225x | -5.18% |
| 2023-03-31 | Rs76.49 Billion ≈ $827.19 Million |
Rs18.13 Billion ≈ $196.10 Million |
0.237x | +62.80% |
| 2022-03-31 | Rs63.16 Billion ≈ $683.08 Million |
Rs9.20 Billion ≈ $99.47 Million |
0.146x | -37.73% |
| 2021-03-31 | Rs48.63 Billion ≈ $525.90 Million |
Rs11.37 Billion ≈ $122.99 Million |
0.234x | -19.73% |
| 2020-03-31 | Rs36.72 Billion ≈ $397.07 Million |
Rs10.70 Billion ≈ $115.68 Million |
0.291x | +44.69% |
| 2019-03-31 | Rs29.82 Billion ≈ $322.46 Million |
Rs6.00 Billion ≈ $64.93 Million |
0.201x | -- |
About Mankind Pharma Ltd
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory d… Read more